BUZZ-Prelude <a href="https://laohu8.com/S/LENZ">Therapeutics</a> rises after FDA clears early-stage trial of blood cancer drug** Shares of drug developer Prelude Therapeutics PRLD.O rise 6.85% to $2.13 premarket
** Company says U.S. FDA has cleared human testing of its experimental drug, PRT12396, for polycythemia vera and myelofibrosis — blood cancers where the body makes too many abnormal blood cells
** PRLD says the early-stage study will assess safety and initial signs of benefit in patients with high-risk disease
** PRT12396 is designed to target a genetic mutation common in both conditions - PRLD
** Company expects to begin enrolling patients by Q2 2026 and says it has an exclusive option deal on the program with Incyte INCY.O
** Shares more than doubled in 2025
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments